Corrigendum - Pharmacological Inhibition of Macrophage Toll-like Receptor 4/Nuclear Factor-kappa B Alleviates Rhabdomyolysis-induced Acute Kidney Injury

Sep 29, 2026

This document presents a formal corrigendum for the research article titled "Pharmacological Inhibition of Macrophage Toll-like Receptor 4/Nuclear Factor-kappa B Alleviates Rhabdomyolysis-induced Acute Kidney Injury," originally published in the Chinese Medical Journal. The authors acknowledge an error involving the misplacement of images during the figure organization process. The provided content includes the updated and corrected Figure 4, which visually demonstrates the experimental findings regarding F4/80-positive cells per high-power field (HPF) under various treatment conditions, including control, glycerol, and pharmacological interventions (Gly+CLI-095 and Gly+P814C). The authors clarify that this correction does not alter the study's overall results or scientific conclusions and offer an apology for the inconvenience.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Corrigendum Overview

Survivin (BIRC5) Correction

Pharmacological Inhibition of Macrophage TLR4 Correction

Corrected Figure 4 Presentation

FAQs

Why was this corrigendum published?

The authors discovered that images in their original article, 'Pharmacological Inhibition of Macrophage Toll-like Receptor 4/Nuclear Factor-kappa B Alleviates Rhabdomyolysis-induced Acute Kidney Injury', were misplaced during figure preparation.

Does this correction change the study's findings?

No, the authors state that the error in figure placement does not affect the results or the conclusions of the original research article.

What does the updated Figure 4 show?

The updated figure shows the number of F4/80-positive cells per high-power field (HPF) in different groups, illustrating the impact of treatments on macrophage infiltration following rhabdomyolysis-induced acute kidney injury.

Sep 29, 2026

Upload by mieayamfan